Mid-cap Health Care company Bio-Techne has moved -2.8% so far today on a volume of 1,240,470, compared to its average of 1,887,857. In contrast, the S&P 500 index moved -1.0%.
Bio-Techne trades -37.99% away from its average analyst target price of $82.36 per share. The 12 analysts following the stock have set target prices ranging from $68.0 to $95.0, and on average have given Bio-Techne a rating of buy.
Anyone interested in buying TECH should be aware of the facts below:
-
Bio-Techne's current price is 192.2% above its Graham number of $17.48, which implies that at its current valuation it does not offer a margin of safety
-
Bio-Techne has moved -18.6% over the last year, and the S&P 500 logged a change of 7.5%
-
Based on its trailing earnings per share of 0.98, Bio-Techne has a trailing 12 month Price to Earnings (P/E) ratio of 52.1 while the S&P 500 average is 29.3
-
TECH has a forward P/E ratio of 23.3 based on its forward 12 month price to earnings (EPS) of $2.19 per share
-
Its Price to Book (P/B) ratio is 3.88 compared to its sector average of 3.53
-
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
-
Based in Minneapolis, the company has 3,100 full time employees and a market cap of $8.07 Billion. Bio-Techne currently returns an annual dividend yield of 0.6%.
